Citadel Advisors
LJPC

Citadel Advisors’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Citadel Advisors’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17,800
Closed -$71K – 15607
2021
Q3 		$71K Sell
17,800
-8,600
-33% -$34.1K ﹤0.01% 13153
2021
Q2 		$113K Buy
26,400
+14,100
+115% +$60.4K ﹤0.01% 12814
2021
Q1 		$52K Sell
12,300
-2,300
-16% -$12.7K ﹤0.01% 12890
2020
Q4 		$57K Sell
14,600
-700
-5% -$2.99K ﹤0.01% 10525
2020
Q3 		$62K Sell
15,300
-34,100
-69% -$141K ﹤0.01% 9525
2020
Q2 		$210K Sell
49,400
-2,900
-6% -$17.7K ﹤0.01% 8460
2020
Q1 		$220K Buy
52,300
+32,400
+163% +$205K ﹤0.01% 7853
2019
Q4 		$78K Buy
+19,900
New +$118K ﹤0.01% 8644
2019
Q3 		– Sell
-16,800
Closed -$155K – 10253
2019
Q2 		$155K Buy
16,800
+2,200
+15% +$16.6K ﹤0.01% 8343
2019
Q1 		$94K Sell
14,600
-9,400
-39% -$61.2K ﹤0.01% 8585
2018
Q4 		$226K Sell
24,000
-15,900
-40% -$239K ﹤0.01% 7693
2018
Q3 		$803K Buy
39,900
+32,900
+470% +$860K ﹤0.01% 5925
2018
Q2 		$204K Sell
7,000
-24,100
-77% -$744K ﹤0.01% 7867
2018
Q1 		$926K Sell
31,100
-41,700
-57% -$1.34M ﹤0.01% 4941
2017
Q4 		$2.34M Buy
72,800
+59,600
+452% +$1.95M ﹤0.01% 3414
2017
Q3 		$459K Sell
13,200
-1,700
-11% -$54.7K ﹤0.01% 5462
2017
Q2 		$444K Sell
14,900
-8,000
-35% -$229K ﹤0.01% 5290
2017
Q1 		$684K Sell
22,900
-1,300
-5% -$33.2K ﹤0.01% 4538
2016
Q4 		$424K Buy
24,200
+1,000
+4% +$19.2K ﹤0.01% 5171
2016
Q3 		$552K Buy
23,200
+13,100
+130% +$247K ﹤0.01% 4711
2016
Q2 		$162K Sell
10,100
-1,400
-12% -$25.1K ﹤0.01% 5974
2016
Q1 		$240K Buy
11,500
+9,900
+619% +$177K ﹤0.01% 5387
2015
Q4 		$43K Sell
1,600
-3,600
-69% -$98.2K ﹤0.01% 7440
2015
Q3 		$145K Buy
+5,200
New +$164K ﹤0.01% 6549

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KT
Kevin Tang $783 AUM 75.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Citadel Advisors's LJPC Position: Q2 2022 in Review

Citadel Advisors sold out of La Jolla Pharmaceutical Company (LJPC) in Q2 2022, closing a stake of 50,873 shares — an estimated $217K sold.

Citadel Advisors first reported a position in LJPC in Q3 2015 and held it in 18 quarters. The position peaked at $8.91M in Q2 2017. 41 funds tracked by Wall St. Rank hold LJPC as of Q2 2022.

  • Citadel Advisors reported no remaining La Jolla Pharmaceutical Company position as of Q2 2022 after selling out during the quarter.
  • Citadel Advisors sold 50,873 La Jolla Pharmaceutical Company shares in Q2 2022, an estimated $217K.
  • Citadel Advisors first reported a position in La Jolla Pharmaceutical Company in Q3 2015 and held it in 18 quarters.
  • Citadel Advisors's La Jolla Pharmaceutical Company position peaked at $8.91M in Q2 2017.
  • 41 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.